Childhood Cancer Survivors have their own unique set of issues that often go unaddressed by health care professionals once treatment has ended and the child enters adulthood. Although the last 20 years have seen growth in survivorship research, this research is rarely filtered down to the people who need it most – the survivors and their families. Dr. Gregory Aune, Pediatric Oncologist, researcher, childhood cancer survivor and advocate, has taken on the position of CKN Editor, Knowledge Translation – Childhood Cancer Survivorship. His goal is simple: to help empower childhood cancer survivors to start a dialogue with their doctors by publishing short, easy-to-read research study summaries, like this one.
THE HEADLINE: Identifying factors associated with platinum-induced ototoxicity in pediatric cancer survivors.
THE RESEARCH: Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Researchers compiled treatment data and audiograms from 451 childhood cancer survivors (CCS) treated at seven pediatric oncology centers in the Netherlands. The study focused on identifying patients that had received platinum agents without cranial irradiation, since no previous studies have looked at ototoxicity outcomes in this population. Risk factors evaluated for the development of hearing impairment included the impact of co-medications, type of platinum agent (cisplatin or carboplatin), and cumulative dose received.